Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JM-010 component B
- Development stage
- Unknown
- Lead developer
- Contera Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
JM-010 component B refers to a specific component group within the investigational drug JM-010, which is being developed primarily for the treatment of levodopa-induced dyskinesia (LID) in Parkinson's disease. JM-010 itself is a **combination drug** comprising buspirone (a 5-HT1A receptor agonist) and zolmitriptan (a 5-HT1B/1D receptor agonist). These components work together to modulate serotonergic neurotransmission, aiming to regulate dopamine function and synaptic activity in both presynaptic dorsal raphe nucleus neurons and postsynaptic medium spiny neurons, addressing dyskinesia[1][4][6]. Component B most likely refers to one of these two drugs within clinical trial arms, though explicit public documentation of which component is assigned as "B" is not available.
- Brand names
- JM-010 component BJM010 component BJM 010 component B
- Other names
- JM-010 component BJM010 component BJM 010 component B
02
Targets
HTR1B (5-Hydroxytryptamine Receptor 1B)HTR1D (5-hydroxytryptamine receptor 1D)HTR1F (Serotonin 5-HT1F receptor)
Beyond the preview
Go deeper on JM-010 component B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JM-010 component B.